Tianyin Pharmaceutical Co., Inc. announced that the relocation and construction cost is estimated to be $25 million for phase one, which is scheduled to be completed in the calendar year 2013 and will expand the current capacity by 30%. For phase two of the QLF project, an additional $10 million in capital investment may be made to double the current capacity in the following years if demand requires.

Tianyin Pharmaceutical Co., Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2013. For the quarter, the company reported sales of $15,525,694 compared to $14,358,800 a year ago. Income from operations was $1,792,801 compared to $1,292,137 a year ago. Income before provision for income tax was $1,732,868 compared to $1,261,452 a year ago. Net income was $1,258,487 compared to $893,114 a year ago. Net income attributable to the company was $1,268,709 compared to $893,137 a year ago. Basic and diluted earnings per share were $0.04 compared to $0.03 a year ago. Comprehensive income attributable to the company was $1,796,138 compared to $1,743,384 a year ago. Increase in net income and the improvement in net margin were predominantly a direct result of improvements in gross margin with a reasonable sales and marketing expenditure. For the nine months, the company reported sales of $49,100,689 compared to $50,124,079 a year ago. Income from operations was $6,536,022 compared to $5,491,872 a year ago. Income before provision for income tax was $6,353,661 compared to $5,625,896 a year ago. Net income was $4,627,470 compared to $4,081,901 a year ago. Net income attributable to the company was $4,674,276 compared to $4,155,982 a year ago. Basic and diluted earnings per share were $0.16 compared to $0.14 a year ago. Comprehensive income attributable to the company was $5,315,669 compared to $6,261,834 a year ago. Net cash provided by operating activities were $811,434 compared to $4,588,737 a year ago. Additions to property and equipment were $1,697,741 compared to $2,733,195 a year ago. The company expects to deliver revenue growth of approximately 5% to 10% in fiscal year 2013 at a 10% net margin.

Tianyin Pharmaceutical Co., Inc., Q3 2013 Earnings Call, May 15, 2013